

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
5.2	14.04.2025	402650-00021	30.09.2023
			Date of first issue: 11.12.2015

Section 1: Identification

Product name : Ribavirin Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON) 0800 243 622 (0800
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

Section 2: Hazard identification**GHS Classification**

Germ cell mutagenicity : Category 2

Reproductive toxicity : Category 1

Specific target organ toxicity - : Category 3
single exposure

Specific target organ toxicity - : Category 1 (Blood)
repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H335 May cause respiratory irritation.
H341 Suspected of causing genetic defects.
H360Df May damage the unborn child. Suspected of damaging
fertility.
H372 Causes damage to organs (Blood) through prolonged or

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
5.2	14.04.2025	402650-00021	30.09.2023
			Date of first issue: 11.12.2015

repeated exposure if swallowed.

Precautionary statements

:

Prevention:

P201 Obtain special instructions before use.

P261 Avoid breathing dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell.

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

Section 3: Composition/information on ingredients

Substance / Mixture

: Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Ribavirin	36791-04-5	>= 50 -< 70
Cellulose	9004-34-6	>= 10 -< 20
Magnesium stearate	557-04-0	>= 1 -< 10

Section 4: First-aid measures

General advice

: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled

: If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact

: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

In case of eye contact	:	Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse. If in eyes, rinse well with water.
If swallowed	:	Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation. May cause respiratory irritation. Suspected of causing genetic defects. May damage the unborn child. Suspected of damaging fertility. Causes damage to organs through prolonged or repeated exposure if swallowed.
Protection of first-aiders	:	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	:	Treat symptomatically and supportively.

Section 5: Fire-fighting measures

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire-fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion products	:	Carbon oxides Metal oxides
Specific extinguishing methods	:	Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

Section 6: Accidental release measures

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air.
Add excess liquid to allow the material to enter into solution.
Soak up with inert absorbent material.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

Section 7: Handling and storage

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

- Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm ²	Internal
		TWA	40 µg/m ³ (OEB 3)	Internal
Cellulose	9004-34-6	WES-TWA	10 mg/m ³	NZ OEL
		TWA	10 mg/m ³	ACGIH
Magnesium stearate	557-04-0	WES-TWA	10 mg/m ³	NZ OEL
		TWA (Inhalable particulate matter)	10 mg/m ³	ACGIH
		TWA (Respirable particulate matter)	3 mg/m ³	ACGIH

- Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Personal protective equipment

Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	:	Particulates type
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Section 9: Physical and chemical properties

Appearance	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	No data available

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes	:	Inhalation Skin contact Ingestion Eye contact
-----------------	---	--

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:**Ribavirin:**

Acute oral toxicity : LD50 (Rat): 4,116 - 5,584 mg/kg
LD50 (Mouse): > 10,000 mg/kg
LD50 (Dog): >= 1,500 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 1,554 - 1,758 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): 1,268 mg/kg
Application Route: Intraperitoneal

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Components:**Ribavirin:**

Remarks : No data available
May irritate skin.

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available
May irritate eyes.

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitisation**Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**Ribavirin:**

Remarks : No data available

Magnesium stearate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Chronic toxicity**Germ cell mutagenicity**

Suspected of causing genetic defects.

Components:**Ribavirin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Rodent cell line
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: negative

Genotoxicity in vivo : Test Type: dominant lethal test
Species: Rat
Result: negative

Test Type: Mouse Lymphoma
Species: Mouse
Result: positive

Test Type: Micronucleus test
Species: Mouse
Result: positive

Germ cell mutagenicity - Assessment : Positive result(s) from in vivo mammalian somatic cell mutagenicity tests.

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:**Ribavirin:**

Species : Mouse
Application Route : Oral
Exposure time : 6 Months
LOAEL : 75 mg/kg body weight
Result : negative
Target Organs : Blood, Testes
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 10 mg/kg body weight
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

Species : Mouse
Application Route : Oral
Exposure time : 18 Months
Result : negative
Remarks : The mechanism or mode of action may not be relevant in humans.

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

May damage the unborn child. Suspected of damaging fertility.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Components:**Ribavirin:**

Effects on fertility

: Test Type: Fertility
Species: Rat, male
Application Route: Intraperitoneal injection
Fertility: LOAEL: < 20 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Mouse, male
Application Route: Oral
Fertility: LOAEL: 35 mg/kg body weight
Symptoms: Reduced fertility
Result: positive

Test Type: Fertility
Species: Rat, females
Application Route: Oral
Fertility: NOAEL: 10 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Test Type: Fertility
Species: Rat, male
Application Route: Oral
Fertility: NOAEL: 160 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development

: Test Type: Development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: <= 1 mg/kg body weight
Symptoms: Reduced body weight, Reduced number of viable fetuses, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Development
Species: Rabbit, female
Application Route: Oral
General Toxicity Maternal: LOAEL: 1 mg/kg body weight
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Symptoms: Reduced body weight, Skeletal malformations
Result: Embryotoxic effects and adverse effects on the off-spring were detected.

Test Type: Development
Species: Hamster
Application Route: Oral
Developmental Toxicity: LOAEL: 2.5 mg/kg body weight
Symptoms: Skeletal and visceral variations, Total Resorptions

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

/ resorption rate

Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: NOAEL: 0.3 mg/kg body weight

Embryo-foetal toxicity: LOAEL: 1 mg/kg body weight

Symptoms: Skeletal malformations

Result: positive

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Clear evidence of adverse effects on development, based on animal experiments.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Magnesium stearate:

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure

May cause respiratory irritation.

Components:**Ribavirin:**

Assessment : May cause respiratory irritation.

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

STOT - repeated exposure

Causes damage to organs (Blood) through prolonged or repeated exposure if swallowed.

Components:**Ribavirin:**

Exposure routes	: Ingestion
Target Organs	: Blood
Assessment	: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Ribavirin:**

Species	: Monkey
LOAEL	: 30 mg/kg
Exposure time	: 10 d
Target Organs	: Blood, Gastrointestinal tract

Species	: Rat
NOAEL	: 7.6 mg/kg
Application Route	: Inhalation
Exposure time	: 90 d
Target Organs	: Blood, Lungs

Species	: Dog
NOAEL	: 5 mg/kg
Application Route	: Oral
Exposure time	: 1 yr
Target Organs	: Blood, Gastrointestinal tract

Species	: Mouse
NOAEL	: 20 mg/kg
Application Route	: Oral
Exposure time	: 18 Months
Target Organs	: Blood, Cardio-vascular system

Cellulose:

Species	: Rat
NOAEL	: $\geq 9,000$ mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days

Magnesium stearate:

Species	: Rat
NOAEL	: > 100 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****Ribavirin:**

Inhalation	:	Symptoms: Headache, Dizziness Remarks: Based on Human Evidence
Skin contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Eye contact	:	Remarks: May cause eye irritation. Based on Human Evidence
Ingestion	:	Symptoms: blood effects, immune system effects, anorexia, Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver function change, Gastrointestinal disturbance

Section 12: Ecological information**Ecotoxicity****Components:****Ribavirin:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 6.9 mg/l Exposure time: 96 h Method: OECD Test Guideline 201
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l Exposure time: 48 h
------------------	---	---

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
5.2	14.04.2025	402650-00021	30.09.2023
			Date of first issue: 11.12.2015

Remarks: Based on data from similar materials

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

Bioaccumulative potential**Components:****Ribavirin:**

Partition coefficient: n-octanol/water : log Pow: 0.971

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

Section 13: Disposal considerations**Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

Section 14: Transport information**International Regulations****UNRTDG**

UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Environmentally hazardous	:	no

IATA-DGR

UN/ID No.	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Packing instruction (cargo aircraft)	:	Not applicable
Packing instruction (passenger aircraft)	:	Not applicable

IMDG-Code

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
EmS Code	: Not applicable
Marine pollutant	: Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**NZS 5433**

UN number	: Not applicable
Proper shipping name	: Not applicable
Class	: Not applicable
Subsidiary risk	: Not applicable
Packing group	: Not applicable
Labels	: Not applicable
Hazchem Code	: Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information**Safety, health and environmental regulations/legislation specific for the substance or mixture****HSNO Approval Number**

not allocated

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

Section 16: Other information

Revision Date	: 14.04.2025
---------------	--------------

Further information

Sources of key data used to	: Internal technical data, data from raw material SDSs, OECD
-----------------------------	--

Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

compile the Safety Data Sheet

eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	14.04.2025	402650-00021	Date of first issue: 11.12.2015

NZ / EN